Earl Brien Net Worth

The estimated Net Worth of Earl W Brien is at least $53.1 millier dollars as of 14 August 2020. Earl Brien owns over 150,000 units of LadRx Corp stock worth over $53,122 and over the last 8 years he sold CYTR stock worth over $0. In addition, he makes $0 as Director at LadRx Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Earl Brien CYTR stock SEC Form 4 insiders trading

Earl has made over 1 trades of the LadRx Corp stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 150,000 units of CYTR stock worth $39,000 on 14 August 2020.

The largest trade he's ever made was exercising 150,000 units of LadRx Corp stock on 14 August 2020 worth over $39,000. On average, Earl trades about 30,000 units every 0 days since 2016. As of 14 August 2020 he still owns at least 590,247 units of LadRx Corp stock.

You can see the complete history of Earl Brien stock trades at the bottom of the page.

Earl Brien biography

Dr. Earl W. Brien M.D. serves as Director of the Company. e is a renowned orthopedic and sarcoma surgeon who is a Professor of Orthopedic Surgery and also the Surgical Director of the Sarcoma Service at Cedars Sinai Medical Center in Los Angeles, California. After completing his matriculation as a Fellow at Memorial Sloan Kettering Cancer Center and the Hospital for Special Surgery in musculoskeletal tumors and metabolic bone disease respectively, he became the Director of the Musculoskelatal Tumor Program and Metabolic Bone Disease Center at Orthopedic Hospital. Dr. Brien is the recipient of numerous grants, with an extensive bibliography of peer-reviewed articles spanning more than 20 years to his credit. He has also presented annually at national and international meetings for the past 20 years. From 1993 until 2004, he served as the Cancer Commission Chairman and Cancer Liaison Physician for the American College of Surgeons Commission on Cancer at Orthopedic Hospital. Our board of directors believes that Dr. Brien is highly qualified to serve as a member of the board because of his wide-ranging experience with sarcoma patients in particular, and his expertise in medical research and other matters related to the operation of a biotechnology company.

How old is Earl Brien?

Earl Brien is 60, he's been the Director of LadRx Corp since 2016. There are 6 older and 2 younger executives at LadRx Corp. The oldest executive at LadRx Corp is Louis Ignarro, 79, who is the Independent Director.

What's Earl Brien's mailing address?

Earl's mailing address filed with the SEC is 11726 SAN VICENTE BLVD., SUITE 650, , LOS ANGELES,, CA, 90049.

Insiders trading at LadRx Corp

Over the last 21 years, insiders at LadRx Corp have traded over $0 worth of LadRx Corp stock and bought 3,710,406 units worth $8,711,088 . The most active insiders traders include Steven A Kriegsman, Scott Bradford Patterson et Max Link. On average, LadRx Corp executives and independent directors trade stock every 177 days with the average trade being worth of $22,531. The most recent stock trade was executed by Earl W Brien on 14 August 2020, trading 150,000 units of CYTR stock currently worth $39,000.

What does LadRx Corp do?

Complete history of Earl Brien stock trades at LadRx Corp

LadRx Corp executives and stock owners

LadRx Corp executives and other stock owners filed with the SEC include:

• Steven Kriegsman,
  Chairman of the Board, Chief Executive Officer
• Steven A. Kriegsman,
  Chief Exec. Officer
• John Caloz,
  Chief Financial Officer, Chief Accounting Officer, IR Contact Officer
• John Y. Caloz,
  CFO, Treasurer & Sr. VP
• Louis Ignarro,
  Independent Director
• Joel Caldwell,
  Director
• Earl Brien,
  Director
• Dr. Felix Kratz Ph.D.,
  Sr. VP, Drug Devel.
• Cristina Newman,
  Corp. Sec.
• Terri Stevens,
  Chief Bus. Officer
• Molly Painter,
  Pres of USA and Head of Launch & Commercial Operations
• Molly Carey Poarch,
  Global & U.S. Head of Corp. Communications
• Jennifer K. Simpson,
  Director
• Anita J Chawla,
  Director
• Daniel J Levitt,
  Chief Medical Officer
• Joseph Rubinfeld,
  Director
• Olivia C Ware,
  Chief Commercial Officer
• Douglas Scott Wieland,
  Sr. VP - Drug Development
• Felix Kratz,
  Vice President Drug Discovery
• Herbert H Jr Mcdade,
  
• Alexander L Cappello,
  Director
• Raymond C Jr Carnahan,
  
• Ben Levin,
  Gen.Cnsl/VP Legal Affairs/Secy
• Eric Jay Selter,
  Director
• Cheryl Cohen,
  Director
• Scott Bradford Patterson,
  10% owner
• Marvin R Selter,
  Director
• Richard J Wennekamp,
  Director
• Max Link,
  Director
• David Scott Geyer,
  Sr. V.P. of Manufacturing
• Mitchell K Fogelman,
  Chief Financial Officer
• Jack R Barber,
  Sr VP - Drug Development
• Shi Chung Ng,
  Sr. VP Research & Development
• Matt Natalizio,
  Chief Financial Officer
• Mark Tepper,
  Vice President
• Stephen Snowdy,
  Chief Executive Officer